Neuraminidase inhibitor R-125489 - A promising drug for treating influenza virus: Steered molecular dynamics approach

Biochemical and Biophysical Research Communications

Volumn 410, Issue 3, 2011, Pages 688-691

  Mai, Binh Khanh ^a   Li, Mai Suan ^b  

^a INSTITUTE FOR COMPUTATIONAL SCIENCE AND TECHNOLOGY   (Viet Nam)

^b INSTITUTE OF PHYSICS   (Poland)

Author keywords

Drug; Influenza virus; Neuraminidase inhibitor; Rupture force; Steered molecular dynamics

Indexed keywords

LANINAMIVIR; LANINAMIVIR OCTANOATE; OSELTAMIVIR; SIALIDASE; ZANAMIVIR;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG BINDING; INFLUENZA; INFLUENZA VIRUS; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H2N2; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS A H5N1; MOLECULAR DYNAMICS; PRIORITY JOURNAL; SIMULATION; VIRUS STRAIN;

ANTIVIRAL AGENTS; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; MOLECULAR DYNAMICS SIMULATION; MUTATION; NEURAMINIDASE; ZANAMIVIR;

ORTHOMYXOVIRIDAE;

EID: 79960059801     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.06.057     Document Type: Article

References (34)

1. Palese P. Influenza: old and new threats. Nat. Med. 2004, 10:S82-S87.
2. Hsieh Y.-C., T-Z Wu., Liu D.-P., Shao P.-L., Chang L.-Y., Lu C.-Y., Lee C.-Y., Huang F.-Y., Huang L.-M. Influenza pandemics: past, present and future. J. Formos. Med. Assoc. 2006, 105:1-6.
3. Ferguson N.M., Fraser C., Donnelly C.A., Ghani A.C., Anderson R.M. Public health risk from the avian H5N1 influenza epidemic. Science 2004, 304:968-969.
4. Yen H.-L., Webster R.G. Pandemic influenza as a current threat. Curr. Top. Microbiol. Immunol. 2009, 333:3-24.
5. WHO, Pandemic (H1N1) 2009 briefing note 4. Available from: <>. (Accessed July 24, 2009). http://www.who.int/csr/disease/swineflu/notes/h1n1_situation_20090724/en/index.html.
6. Neumann G., Noda T., Kawaoka Y. Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature 2009, 459:931-939.
7. WHO, H1N1 in post-pandemic period. Available from: <>. (Accessed August 10, 2010). http://www.who.int/mediacentre/news/statements/2010/h1n1_vpc_20100810/en/index.html.
8. Hay A.J., Wolstenholme A.J., Skehel J.J., Smith M.H. The molecular basis of the specific anti-influenza action of amantadine. EMBO J. 1985, 4:3021-3024.
9. Pinto L.H., Lamb R.A. The M2 proton channels of influenza A and B viruses. J. Biol. Chem. 2006, 281:8997-9000.
10. Stephenson I., Nicholson K.G. Chemotherapeutic control of influenza. J. Antimicrob. Chemother. 1999, 44:6-10.
11. Monto A.S., Arden N.H. Implications of viral resistance to amantadine in control of influenza A. Clin. Infect. Dis. 1992, 15:362-367.
12. Moscona A. Neuraminidase inhibitors for influenza. N. Engl. J. Med. 2005, 353:1363-1373.
13. Le Q.M., Kiso M., Someya K., Sakai Y.T., Nguyen T.H., Nguyen K.H.L., Pham N.D., Nguyen H.H., Yamada S., Muramoto Y., Horimoto T., Takada A., Goto H., Suzuki T., Suzuki Y., Kawaoka Y. Avian flu: isolation of drug-resistant H5N1 virus. Nature 2005, 437:1108.
14. Webster R.G., Govorkova E.A. H5N1 influenza-continuing evolution and spread. N. Engl. J. Med. 2006, 355:2174-2177.
15. Centers for Disease Control and Prevention (CDC), Oseltamivir-resistant novel influenza A (H1N1) virus infection in two immunosuppressed patients - Seattle, Washington, MMWR Morb. Mortal. Wkly. Rep. (2009) 893-896.
16. Centers for Disease Control and Prevention (CDC), Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis - North Carolina, MMWR Morb. Mortal. Wkly. Rep. (2009) 969-972.
17. WHO, Pandemic (H1N1) 2009 briefing note 1. Available from: <>. (Accessed July 8, 2009). http://www.who.int/csr/disease/swineflu/notes/h1n1_antiviral_resistance_20090708/en/index.html.
18. Yamashita M., Tomozawa T., Kakuta M., Tokumitsu A., Nasu H., Kubo S. CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, Shows long-acting anti-influenza virus activity. Antimicrob. Agents Chemother. 2009, 53:186-192.
19. Kiso M., Kubo S., Ozawa M., Le Q.M., Nidom C.A., Yamashita M., Kawaoka Y. Efficacy of the new neuraminidase inhibitor CS-8958 against H5N1 influenza viruses. PLoS Pathog. 2010, 6:e1000786.
20. Kubo S., Tomozawa T., Kakuta M., Tokumitsu A., Yamashita M. Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration. Antimicrob. Agents Chemother. 2010, 54:1256-1264.
21. Sugaya N., Ohashi Y. Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection. Antimicrob. Agents Chemother. 2010, 54:2575-2582.
22. M. Kiso, K. Shinya, M. Shimojima, R. Takano, K. Takahashi, H. Katsura, S. Kakugawa, M. Thi Quynh Le, M. Yamashita, Y. Furuta, M. Ozawa, Y. Kawaoka, Characterization of oseltamivir-resistant 2009 H1N1 pandemic influenza A viruses, PLoS Pathog. 6 (2010) e1001079.
23. Isralewitz B., Gao M., Schulten K. Steered molecular dynamics and mechanical functions of proteins. Curr. Opin. Struct. Biol. 2001, 11:224-230.
24. Li M.S. Secondary structure, mechanical stability and location of transition state of proteins. Biophys. J. 2007, 93:2644-2654.
25. Kumar S., Li M.S. Biomolecules under mechanical force. Physics Reports 2010, 486:1-73.
26. Colizzi F., Perozzo R., Scapozza L., Recanatini M., Cavalli A. Single-molecule pulling simulations can discern active from inactive enzyme inhibitors. J. Am. Chem. Soc. 2010, 132:7361-7371.
27. Mai B.K., Viet M.H., Li M.S. Top-Leads for Swine Influenza A/H1N1 Virus Revealed by Steered Molecular Dynamics Approach. J. Chem. Inf. Model. 2010, 50:2236-2247.
28. Allouche A.-R. Gabedit-A graphical user interface for computational chemistry softwares. J. Comput. Chem. 2011, 32:174-182.
29. W. van Gunsteren, S.R. Billeter, A.A. Eising, P.H. Hunenberger, P. Kruger, A.E. Mark, W.R.R. Scott, I.G. Tironi, Biomolecular Simulation: The GROMOS96 Manual and User Guide; Vdf Hochschulverlag AG an der ETH Zurich: Zurich, 1996.
30. Aalten D.M.F., Bywater R., Findlay J.B.C., Hendlich M., Hooft R.W.W., Vriend G. PRODRG, A program for generating molecular topologies and unique molecular descriptors from coordinates of small molecules. J. Comput. Aided. Mol. Des. 1996, 10:255-262.
31. Trott O., Olson A.J. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 2010, 31:455-461.
32. Hess B., Kutzner C., van der Spoel D., Lindahl E. GROMACS 4: algorithms for highly efficient, load-balanced, and scalable molecular simulation. J. Chem. Theory Comput. 2008, 4:435-447.
33. Srinivasan J., Cheatham T.E., Cieplak P., Kollman P.A., Case D.A. Continuumsolvent studies of the stability of DNA, RNA, and Phosphoramidate-DNA helices. J. Am. Chem. Soc. 1998, 120:9401-9409.
34. Collins P.J., Haire L.F., Lin Y.P., Liu J., Russell R.J., Walker P.A., Skehel J.J., Martin S.R., Hay A.J., Gamblin S.J. Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants. Nature 2008, 453:1258-1261.